Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | Retrospective analysis of lenalidomide and thalidomide in myelofibrosis

Andrew Kuykendall • 25 Aug 2020
Myelofibrosis Myeloproliferative Neoplasms Lenalidomide Thalidomide

Andrew Kuykendall, MD, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, explores results from a retrospective analysis of the clinical use and benefit of lenalidomide and thalidomide in myelofibrosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Andrew Kuykendall

Practice-changing findings in MPNs from ASCO 2025
0:57
Practice-changing findings in MPNs from ASCO 2025
Andrew Kuykendall • 1 Jun 2025
The IMproveMF study: combining imetelstat with ruxolitinib for the treatment of myelofibrosis
0:58
The IMproveMF study: combining imetelstat with ruxolitinib for the treatment of myelofibrosis
Andrew Kuykendall • 1 Jun 2025
An overview of novel JAKis in myelofibrosis: which patients benefit from pacritinib & momelotinib?
1:31
An overview of novel JAKis in myelofibrosis: which patients benefit from pacritinib & momelotinib?
Andrew Kuykendall • 1 Jun 2025
Results from the VERIFY trial: the encouraging efficacy of rusfertide in patients with PV
2:32
Results from the VERIFY trial: the encouraging efficacy of rusfertide in patients with PV
Andrew Kuykendall • 1 Jun 2025

Related Videos

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Andrew Kuykendall • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Andrew Kuykendall • 6 Dec 2025
The management of patients with ET or PV during pregnancy
3:32
The management of patients with ET or PV during pregnancy
Andrew Kuykendall • 7 Dec 2025
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
2:37
Preliminary analysis of the FEDORA trial: fedratinib plus ropeginterferon alfa-2b in myelofibrosis
Andrew Kuykendall • 7 Dec 2025
The content of VJHemOnc is intended for healthcare professionals